348 results on '"Xi, Mian"'
Search Results
2. Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape
3. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab
4. Volatile organic compounds in exhaled breath: Applications in cancer diagnosis and predicting treatment efficacy
5. Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
6. Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm
7. Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial
8. Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
9. Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy and Surgery
10. A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
11. Trafficking protein TMED3 promotes esophageal squamous cell carcinoma
12. Risk factors and prognosis for esophageal fistula in patients with esophageal squamous cell carcinoma during radiotherapy
13. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
14. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis
15. Modeling the risk of radiation pneumonitis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
16. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis
17. ASO Visual Abstract: Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy and Surgery
18. ASO Author Reflections: The Prophets of Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Trimodality Therapy
19. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
20. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy
21. TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ
22. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
23. Biofilm Disruption Utilizing α/β Chimeric Polypeptide Molecular Brushes
24. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy
25. Management of metastatic bone disease of melanoma
26. A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial
27. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy
28. Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus
29. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
30. Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies
31. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma
32. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes
33. Efficacy and cost‐effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059)
34. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
35. Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinoma
36. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy
37. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study
38. Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy
39. The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma
40. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma
41. Prognosis of Fibrosarcoma in Patients With and Without a History of Radiation for Nasopharyngeal Carcinoma
42. ASO Visual Abstract: Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy and Surgery
43. Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
44. ASO Author Reflections: The Prophets of Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Trimodality Therapy
45. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
46. Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma.
47. Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma
48. Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy and Surgery
49. 183. IMPACTS OF NEOADJUVANT CHEMORADIOTHERAPY ON THE IMMUNE LANDSCAPE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
50. Comparative Efficacy and Safety of Immunotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.